A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers

Trial Profile

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Athenex
  • Most Recent Events

    • 05 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 22 Jan 2018 Results published in a Athenex media release
    • 22 Jan 2018 According to an Athenex media release, first cohort of the study has been completed (n=6). Study is proceeding towards second cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top